Basilea erhält USD 7.3 Mio.von CARB-X zur Entwicklung des Antibiotikums BAL2420.LptA-Inhibitoren bekämpfen gramnegative Bakterien.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback